First Time Loading...

Healios KK
TSE:4593

Watchlist Manager
Healios KK Logo
Healios KK
TSE:4593
Watchlist
Price: 152 JPY -0.65%
Updated: Apr 25, 2024

Intrinsic Value

Healios KK's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Healios KK engages in the research, development, and sale of cellular and regenerative medicine. [ Read More ]

The intrinsic value of one Healios KK stock under the Base Case scenario is 251.57 JPY. Compared to the current market price of 152 JPY, Healios KK is Undervalued by 40%.

Key Points:
Intrinsic Value
Base Case
251.57 JPY
Undervaluation 40%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Healios KK

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling Healios KK stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Healios KK

Provide an overview of the primary business activities
of Healios KK.

What unique competitive advantages
does Healios KK hold over its rivals?

What risks and challenges
does Healios KK face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Healios KK.

Provide P/S
for Healios KK.

Provide P/E
for Healios KK.

Provide P/OCF
for Healios KK.

Provide P/FCFE
for Healios KK.

Provide P/B
for Healios KK.

Provide EV/S
for Healios KK.

Provide EV/GP
for Healios KK.

Provide EV/EBITDA
for Healios KK.

Provide EV/EBIT
for Healios KK.

Provide EV/OCF
for Healios KK.

Provide EV/FCFF
for Healios KK.

Provide EV/IC
for Healios KK.

Show me price targets
for Healios KK made by professional analysts.

What are the Revenue projections
for Healios KK?

How accurate were the past Revenue estimates
for Healios KK?

What are the Net Income projections
for Healios KK?

How accurate were the past Net Income estimates
for Healios KK?

What are the EPS projections
for Healios KK?

How accurate were the past EPS estimates
for Healios KK?

What are the EBIT projections
for Healios KK?

How accurate were the past EBIT estimates
for Healios KK?

Compare the revenue forecasts
for Healios KK with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Healios KK and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Healios KK against its competitors.

Analyze the profit margins
(gross, operating, and net) of Healios KK compared to its peers.

Compare the P/E ratios
of Healios KK against its peers.

Discuss the investment returns and shareholder value creation
comparing Healios KK with its peers.

Analyze the financial leverage
of Healios KK compared to its main competitors.

Show all profitability ratios
for Healios KK.

Provide ROE
for Healios KK.

Provide ROA
for Healios KK.

Provide ROIC
for Healios KK.

Provide ROCE
for Healios KK.

Provide Gross Margin
for Healios KK.

Provide Operating Margin
for Healios KK.

Provide Net Margin
for Healios KK.

Provide FCF Margin
for Healios KK.

Show all solvency ratios
for Healios KK.

Provide D/E Ratio
for Healios KK.

Provide D/A Ratio
for Healios KK.

Provide Interest Coverage Ratio
for Healios KK.

Provide Altman Z-Score Ratio
for Healios KK.

Provide Quick Ratio
for Healios KK.

Provide Current Ratio
for Healios KK.

Provide Cash Ratio
for Healios KK.

What is the historical Revenue growth
over the last 5 years for Healios KK?

What is the historical Net Income growth
over the last 5 years for Healios KK?

What is the current Free Cash Flow
of Healios KK?

Discuss the annual earnings per share (EPS)
trend over the past five years for Healios KK.

Financials

Balance Sheet Decomposition
Healios KK

Current Assets 7.7B
Cash & Short-Term Investments 6.7B
Receivables 324m
Other Current Assets 637m
Non-Current Assets 7.5B
Long-Term Investments 2.7B
PP&E 674m
Intangibles 4.1B
Other Non-Current Assets 2m
Current Liabilities 5.2B
Accounts Payable 229m
Other Current Liabilities 4.9B
Non-Current Liabilities 6.1B
Long-Term Debt 4B
Other Non-Current Liabilities 2.2B
Efficiency

Earnings Waterfall
Healios KK

Revenue
121m JPY
Cost of Revenue
-13m JPY
Gross Profit
108m JPY
Operating Expenses
-3.5B JPY
Operating Income
-3.4B JPY
Other Expenses
-444m JPY
Net Income
-3.8B JPY

Free Cash Flow Analysis
Healios KK

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

Profitability Score
Profitability Due Diligence

Healios KK's profitability score is 28/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Exceptional Revenue Growth Forecast
Exceptional 1-Year Revenue Growth
Positive Gross Profit
28/100
Profitability
Score

Healios KK's profitability score is 28/100. The higher the profitability score, the more profitable the company is.

Solvency Score
Solvency Due Diligence

Healios KK's solvency score is 33/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Short-Term Solvency
Long-Term Solvency
Average D/E
33/100
Solvency
Score

Healios KK's solvency score is 33/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

Price Targets Summary
Healios KK

Wall Street analysts forecast Healios KK stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Healios KK is 308.55 JPY with a low forecast of 141.4 JPY and a high forecast of 420 JPY.

Lowest
Price Target
141.4 JPY
7% Downside
Average
Price Target
308.55 JPY
103% Upside
Highest
Price Target
420 JPY
176% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

Price
Healios KK

1M 1M
+3%
6M 6M
-6%
1Y 1Y
-49%
3Y 3Y
-91%
5Y 5Y
-92%
10Y 10Y
-91%
Annual Price Range
152
52w Low
115
52w High
325
Price Metrics
Average Annual Return -27.57%
Standard Deviation of Annual Returns 42.36%
Max Drawdown -95%
Shares Statistics
Market Capitalization 13.7B JPY
Shares Outstanding 90 130 022
Percentage of Shares Shorted
N/A

Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Healios KK Logo
Healios KK

Country

Japan

Industry

Biotechnology

Market Cap

13.7B JPY

Dividend Yield

0%

Description

Healios KK engages in the research, development, and sale of cellular and regenerative medicine. The company is headquartered in Chiyoda-Ku, Tokyo-To and currently employs 116 full-time employees. The company went IPO on 2015-06-16. is a Japan-based company mainly engaged in research and development of pharmaceutical products. The firm has compound pharmaceutical products line and induced pluripotent stem cell (iPSC) regenerative medicine product line. The compound pharmaceutical product line contains HLM0021, HLM0022 and HLM0023. The products are ophthalmological surgery adjuvants, mainly contain brilliant blue G-250 (BBG250) which help capsule temporarily safely stained to protect the inner limiting membranes and lens during surgery of vitreous and cataract. The iPSC regenerative medicine product line contains HLCR011 and HLCR012. The products are in the preclinical testing and preparation for trial in Japan, which are candidate of regenerative medicine products. The products are iPS cell derived retinal pigment epithelium (RPE) cell suspension and sheet developed in Japan, United States and Europe.

Contact

TOKYO-TO
Chiyoda-ku
19F, Yurakucho Denki Bldg. North Tower, 1-7-1, Yuraku-cho
https://www.healios.co.jp/

IPO

2015-06-16

Employees

116

Officers

Chairman & CEO
Dr. Tadahisa S. Kagimoto M.D.
CFO, Executive Officer & Internal Director
Mr. Richard P. Kincaid
Executive VP, Chief Medical Officer and In Charge of Development & Human Resources & General Affairs
Mr. Masanori Sawada M.D., MBA, Ph.D.
Exec. Off., Chief Scientific Off., In Charge of Res. & Manufacturing and Head of Kobe Res. Institute
Mr. Kouichi Tamura Ph.D.
Managing Director
Mr. Yoshinari Matsuda

See Also

Discover More
What is the Intrinsic Value of one Healios KK stock?

The intrinsic value of one Healios KK stock under the Base Case scenario is 251.57 JPY.

Is Healios KK stock undervalued or overvalued?

Compared to the current market price of 152 JPY, Healios KK is Undervalued by 40%.